OraSure Technologies, Inc. (OSUR) News
OraSure Technologies, Inc. (OSUR)
Today's Latest Price: $13.66 USD
Updated Jan 19 4:00pm
Add OSUR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 185 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
StocksNews Articles for OSUR
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest OSUR News From Around the Web
Below are the latest news stories about Orasure Technologies Inc that investors may wish to consider to help them evaluate OSUR as an investment opportunity.
Aphria (APHA) Looks Good: Stock Adds 6% in SessionAphria (APHA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes. |
OraSure Technologies Announces 2021 Annual Meeting DateBETHLEHEM, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2021 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 18, 2021. The record date for the Meeting will be March 26, 2021. Only stockholders of record as of the close of business on the record date will be entitled to vote at the 2021 Annual Meeting, or any adjournment(s) or postponement(s) of the Meeting. This will be a completely virtual meeting, conducted as a live webcast. Further details regarding the Meeting will be provided at a later date. About OraSure TechnologiesOraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, t... |
OraSure Technologies to Present at the 39th Annual J.P. Morgan Healthcare ConferenceBETHLEHEM, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 39th Annual J.P. Morgan Healthcare Conference. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on January 12, 2021, at approximately 2:50 PM Eastern Standard Time (11:50 PM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link. A replay of the webcast will be available on OraSure Technologie... |
Global Preliminary Screening Tests Market Size, Industry Status and Growth opportunities for Leading Players-Abbott, BD, Bio-rad Laboratories, Inc., Cepheid., Hologic Inc., Meridian Bioscience, Inc., OraSure Technologies, IncThe demand for preliminary screening tests is projected to achieve market share over the 2020 to 2027 forecast period. Data Bridge Market Research analyses the demand in the projected timeframe to expand at a CAGR of 7.11 percent. Preliminary Screening |
OraSure’s OMNIgene®·ORAL Device Included in EUA Amendment Granted to 3B BlackBio Biotech India for SARS-CoV-2 TestOTTAWA, Dec. 23, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its OMNIgene®·ORAL (OM/OME-505) collection device was included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) amendment granted to 3B BlackBio Biotech, one of the leading suppliers and developers for RT-PCR diagnostic assays in India. This is the seventh customer EUA that includes a collection device from the company’s DNA Genotek subsidiary. This EUA amendment will allow 3B BlackBio Biotech’s North American distributor, Genophyll Enterprises, to expand saliva COVID-19 PCR-based viral diagnostic testing across the U.S. as well... |
OraSure Technologies Provides Update on Its Emergency Use Authorization Application for Its Lab-based Oral Fluid SARS-CoV-2 Antibody TestBETHLEHEM, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today disclosed that the U.S. Food and Drug Administration (FDA) has requested additional information as part of its review of the Company’s application for Emergency Use Authorization (EUA) for its laboratory-based oral fluid SARS-CoV-2 antibody test. The OraSure SARS-CoV-2 Antibody ELISA is intended for qualitative detection of total antibodies to SARS-CoV-2 in human oral fluid specimens collected with the OraSure Oral Antibody Collection Device. At the FDA’s request, the Company intends to resubmit two separate EUAs for the ELISA and the oral specimen collection device. In addition, the FDA has requested that additio... |
OraSure Technologies to Present at the 2020 Evercore ISI HealthCONx ConferenceBETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 2020 Evercore ISI HealthCONx Conference. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on December 3, 2020, at approximately 9:40 AM Eastern Standard Time (6:40 AM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link. A replay of the webcast will be available on OraSure Technologies’ web site for fourteen days. Alternatively, you can acce... |
OraSure Technologies to Commemorate World AIDS Day by Ringing NASDAQ Closing BellBETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in the fight against HIV, today announced its plans to commemorate World AIDS Day. On Tuesday, Dec. 1st, OraSure will ring the closing bell for the NASDAQ Stock Market, in a virtual ceremony that will be livestreamed. “A year ago, on World AIDS Day 2019, it appeared that eliminating the HIV epidemic was within our grasp. Today, we’re in a far different place as COVID-19 has disrupted the delivery of testing, services and care, reversing many of the gains we’ve made,” said OraSure President and CEO, Stephen S. Tang, Ph.D. “Today, on World AIDS Day 2020, it’s time to put a stake in the ground: We cannot let the HIV epidemic take a back seat to COVID-19. At OraSure, we are proud of the wa... |
Global Preliminary Screening Tests Market Size, Industry Status And Growth Opportunities For Leading Players|Akers Biosciences, Inc., Abbott, BD, Bio-rad Laboratories, Inc., Cepheid., Hologic Inc., Meridian Bioscience, Inc., OraSure Technologies, IncData Bridge Market Research has recently added a concise research on the Preliminary Screening Tests Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by |
At-Home Testing Kits Market to Show Tremendous Growth by 2027 | Leading Players-Abbott, OraSure Technologies, Inc., BD, Nureca Inc. USA, F. Hoffmann-La Roche LtdDBMR has added a new report titled At-Home Testing Kits Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This At-Home Testing Kits Market report is |